Health‐Related Quality of Life and Preference‐Based Utility Index in People With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A National Registry Study
Pediatric Pulmonology · 2026-11 · 61 (11)
DOI: 10.1002/ppul.71905 ↗Abstract
ABSTRACT Background Elexacaftor/tezacaftor/ivacaftor (ETI) has transformed cystic fibrosis (CF) by improving outcomes and survival. We aimed to evaluate changes in health‐related quality of life (HRQoL) and preference‐weighted utility index following ETI initiation in children and adolescents/adults with CF. Methods In this nationwide Danish CF cohort, HRQoL was assessed using age‐appropriate Cystic Fibrosis Questionnaire–Revised (CFQ‐R) versions before and after ETI initiation. Utility indices were derived from the adolescent/adult CFQ‐R using the CFQ‐R‐8D algorithm. Linear mixed‐effect models estimated changes from pre‐ETI to 6, 12, and 24 months. Results Among 387 participants (90 children, 297 adolescents/adults), children had higher pre‐ETI CFQ‐R scores across most domains compared to adolescents/adults. Compared to pre‐ETI, respiratory functioning improved in children at 6 months (5.1; 95% CI 1.2; 8.9) and 12 months (5.6; 95% CI 1.7; 9.6), but not at 24 months (3.5; 95% CI −1.5; 8.6). Adolescents/adults showed improvements at 6 months (12.6; 95% CI 10.2–14.9), 12 months (11.9; 95% CI 9.5–14.4), and 24 months (11.4; 95% CI 8.5–14.3) in respiratory functioning . In children, eating and digestion also improved, while other domains showed heterogeneous patterns with little change. Adolescents/adults improved across most domains except digestion . CFQ‐R utility score showed small increases. Conclusion ETI was associated with improvements across most HRQoL domains in adolescents/adults, while digestion remained unchanged. In contrast, digestion improved in children as well as respiratory functioning and eating . Modest psychosocial and utility changes likely reflect high pre‐ETI levels. The results underscore the need for age‐specific interpretation and refinement of HRQoL measures in the modulator era.
EUVIMED